|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stamey TA, Yang N, Hay AR, McNeal JE,
Freiha FS and Redwine E: Prostate-specific antigen as a serum
marker for adenocarcinoma of the prostate. N Engl J Med.
317:909–916. 1987.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mistry K and Cable G: Meta-analysis of
prostate-specific antigen and digital rectal examination as
screening tests for prostate carcinoma. J Am Board Fam Pract.
16:95–101. 2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Oberaigner W, Siebert U, Horninger W,
Klocker H, Bektic J, Schäfer G, Frauscher F, Schennach H and
Bartsch G: Prostate-specific antigen testing in Tyrol, Austria:
Prostate cancer mortality reduction was supported by an update with
mortality data up to 2008. Int J Public Health. 57:57–62.
2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L,
Lilja H, et al: ERSPC Investigators. Screening and prostate cancer
mortality: Results of the European Randomised Study of Screening
for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet.
384:2027–2035. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Aus G, Bergdahl S, Lodding P, Lilja H and
Hugosson J: Prostate cancer screening decreases the absolute risk
of being diagnosed with advanced prostate cancer - results from a
prospective, population-based randomized controlled trial. Eur
Urol. 51:659–664. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kerkhof M, Roobol MJ, Cuzick J, Sasieni P,
Roemeling S, Schröder FH and Steyerberg EW: Effect of the
correction for noncompliance and contamination on the estimated
reduction of metastatic prostate cancer within a randomized
screening trial (ERSPC section Rotterdam). Int J Cancer.
127:2639–2644. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pinsky PF, Prorok PC, Yu K, Kramer BS,
Black A, Gohagan JK, Crawford ED, Grubb RL and Andriole GL:
Extended mortality results for prostate cancer screening in the
PLCO trial with median follow-up of 15 years. Cancer. 123:592–599.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pinsky PF, Blacka A, Kramer BS, Miller A,
Prorok PC and Berg C: Assessing contamination and compliance in the
prostate component of the Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial. Clin Trials. 7:303–311.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shoag JE, Mittal S and Hu JC: Reevaluating
PSA testing rates in the PLCO trial. N Engl J Med. 374:1795–1796.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Martin RM, Donovan JL, Turner EL, Metcalfe
C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, et al:
CAP Trial Group: Effect of a low-intensity PSA-based screening
intervention on prostate cancer mortality: The CAP randomized
clinical trial. JAMA. 319:883–895. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fenton JJ, Weyrich MS, Durbin S, Liu Y,
Bang H and Melnikow J: Prostate-specific antigen-based screening
for prostate cancer: Evidence report and systematic review for the
US Preventive Services Task Force. JAMA. 319:1914–1931.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ilic D, Djulbegovic M, Jung JH, Hwang EC,
Zhou Q, Cleves A, Agoritsas T and Dahm P: Prostate cancer screening
with prostate-specific antigen (PSA) test: A systematic review and
meta-analysis. BMJ. 362(k3519)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mottet N, Bellmunt J, Bolla M, Briers E,
Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau
S, et al: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1:
Screening, diagnosis, and local treatment with curative intent. Eur
Urol. 71:618–629. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Carroll PR, Parsons JK, Andriole G,
Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW,
Epstein JI, et al: NCCN clinical practice guidelines prostate
cancer early detection, version 2.2015. J Natl Compr Canc Netw.
13:1534–1561. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Grossman DC, Curry SJ, Owens DK,
Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M,
Epling JW Jr, Kemper AR, et al: US Preventive Services Task Force:
Screening For Prostate Cancer: US preventive services task force
recommendation statement. JAMA. 319:1901–1913. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mok Y, Kimm H, Shin SY, Jee SH and Platz
EA: Screening prostate-specific antigen concentration and prostate
cancer mortality: The Korean Heart Study. Urology. 85:1111–1116.
2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu Y, Xiao G, Zhou JW, Yang JK, Lu L,
Bian J, Zhong L, Wei QZ, Zhou QZ, Xue KY, et al: Optimal starting
age and baseline level for repeat tests: Economic concerns of psa
screening for chinese men - 10-year experience of a single center.
Urol Int. 104:230–238. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sakai N, Taguri M, Kobayashi K, Noguchi S,
Ikeda S, Koh H, Satomi Y and Furuhata A: Clinical outcomes of
prostate cancer patients in Yokosuka City, Japan: A comparative
study between cases detected by prostate-specific antigen-based
screening in Yokosuka and those detected by other means. Int J
Urol. 22:747–752. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Okihara K, Kitamura K, Okada K, Mikami K,
Ukimura O and Miki T: Ten year trend in prostate cancer screening
with high prostate-specific antigen exposure rate in Japan. Int J
Urol. 15:156–161. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ito K, Kakehi Y, Naito S and Okuyama A:
Japanese Urological Association. Japanese Urological Association
guidelines on prostate-specific antigen-based screening for
prostate cancer and the ongoing cluster cohort study in Japan. Int
J Urol. 15:763–768. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tabei T, Taguri M, Sakai N, Koh H, Yosida
M, Fujikawa A, Nirei T, Tsutsumi S, Ito H, Furuhata S, et al: Does
screening for prostate cancer improve cancer-specific mortality in
Asian men? Real-world data in Yokosuka City 15 years after
introducing PSA-based population screening. Prostate. 80:824–830.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rebbeck TR and Haas GP: Temporal trends
and racial disparities in global prostate cancer prevalence. Can J
Urol. 21:7496–7506. 2014.PubMed/NCBI
|
|
25
|
Bell KJ, Del Mar C, Wright G, Dickinson J
and Glasziou P: Prevalence of incidental prostate cancer: A
systematic review of autopsy studies. Int J Cancer. 137:1749–1757.
2015.PubMed/NCBI View Article : Google Scholar
|
